Brief: Acer Therapeutics Announces Initiation Of Two Investigator-Sponsored Trials Of Acer-801 (Osanetant) In Men With Adenocarcinoma Of The Prostate
05/01/2023 15:07
Jan 5 (Reuters) - Acer Therapeutics Inc ACER.O :
* ACER THERAPEUTICS ANNOUNCES INITIATION OF TWO
INVESTIGATOR-SPONSORED TRIALS OF ACER-801 (OSANETANT) IN MEN
WITH ADENOCARCINOMA OF THE PROSTATE
Source text for Eikon: ID:nGNX4rdCr4
Further company coverage: ACER.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Acer Therapeutics
See all newsBrief: Leading Independent Proxy Advisory Firms Iss And Glass Lewis Recommend Acer Therapeutics Shareholders Vote "For" The Proposed Merger And Related Proposals
U.S. STOCKS ON THE MOVE-UGI, SkyWest, Sage Therapeutics
Acer Therapeutics surges on Zevra buyout deal
Brief: Zevra Therapeutics To Acquire Acer Therapeutics, Expanding Its Rare Disease Portfolio And Adding Commercial Product
Swiss stocks - Factors to watch on August 31